Avalyn Pharma Inc.(AVLN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AVLN Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Avalyn Pharma Inc. (AVLN), a Healthcare sector company. AVLN is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Avalyn Pharma Inc. reports net income of $-28.9M, free cash flow of $-26.3M. Top institutional holders of AVLN by reported 13-F value include FMR, Novo A/S, SR ONE CAPITAL MANAGEMENT, based on the most recent SEC filings. AVLN trades on the Nasdaq exchange and files with the SEC under CIK 1540171. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVLN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Avalyn Pharma Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-28.9M
Free Cash Flow
Q2 2026
$-26.3M
ROIC
Q2 2026
-30.3%
D/E Ratio
Q2 2026
0.04
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProTotal Assets
Total Debt
| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Total Assets | $148.9M | — |
| Total Debt | $0.00 | — |
Get alerted when AVLN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Avalyn Pharma Inc. including:
Top Institutional Holders of AVLN
FMR LLC
$192.1M5,835,259 shNovo Holdings A/S
$127.8M3,883,289 shSR ONE CAPITAL MANAGEMENT, LP
$108.9M3,308,649 shPERCEPTIVE ADVISORS LLC
$88.1M2,675,296 shSUVRETTA CAPITAL MANAGEMENT, LLC
$82.4M2,503,109 shNVP Associates, LLC
$74.7M2,268,404 shWELLINGTON MANAGEMENT GROUP LLP
$72.5M2,201,986 shPRICE T ROWE ASSOCIATES INC /MD/
$57.1M1,735,231 shCatalio Capital Management, LP
$55.2M1,675,830 shT. Rowe Price Investment Management, Inc.
$52.8M1,602,745 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $192.1M | 5,835,259 |
| Novo Holdings A/S | $127.8M | 3,883,289 |
| SR ONE CAPITAL MANAGEMENT, LP | $108.9M | 3,308,649 |
| PERCEPTIVE ADVISORS LLC | $88.1M | 2,675,296 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $82.4M | 2,503,109 |
| NVP Associates, LLC | $74.7M | 2,268,404 |
| WELLINGTON MANAGEMENT GROUP LLP | $72.5M | 2,201,986 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $57.1M | 1,735,231 |
| Catalio Capital Management, LP | $55.2M | 1,675,830 |
| T. Rowe Price Investment Management, Inc. | $52.8M | 1,602,745 |
More Healthcare Companies
View all Healthcare →Put AVLN on your watchlist
Track score changes the day Avalyn Pharma Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AVLN a good stock to buy?
13F Pro's AI-powered analysis of Avalyn Pharma Inc. (AVLN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AVLN are available on the AVLN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AVLN is classified as a small company.
Which hedge funds own AVLN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AVLN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Avalyn Pharma Inc.'s investment landscape.